Drug-resistance analysis of Gram-negative bacilli producing extended-spectrum β-lactamases in lower respiratory tract infection

Abstract

Abstract: Objective To analyze occurrence of Gram-negative bacteria producing extended-spectrum β-lactamase (ESBL) in patients with lower respiratory tract infection and assess their drug sensitivity to provide evidence for clinical management of lower respiratory tract infection with drug-resistant ESBL-producing bacteria. Methods A total of 312 Gram-negative bacterial strains were isolated from patients with lower respiratory tract infection and identified for the presence of ESBL by Vitek ESBL detection test and double-disk synergy tests as well as standard disk diffusion test. The effects of 10 antibacterial drugs on ESBL-producing strains were compared. Results A rate of 20.1% of the isolated strains were identified to produce ESBLs, including Klebsiella Pneumoniae, Escherichia coli, Enterobacter cloacae, Pseudomonas aeruginasa and Klebsiella oxytocla (accounting for 30.1%, 29.1%, 27.0%, 11.3%, and 2.5%, respectively, of the ESBL-producing strains). Imipenem possessed the most powerful antibacterial activity against ESBL-producing strains. Conclusions Attention should be given to lower respiratory tract infections with ESBL-producing Gram-negative bacilli, and imipenem can be the primary choice for fighting such infections.

CLC Number:

R969.3

LONG Jun, Lü Su-cheng. Drug-resistance analysis of Gram-negative bacilli producing extended-spectrum β-lactamases in lower respiratory tract infection[J]. Journal of Southern Medical University, 2004, 24(04): 439-440,444.

References

[1] 王枢群,张邦.医院感染学[M].重庆:科学技术文献出版社重庆分社,1990.1-2.
[2] 赵和平,杨芸.180例医院感染病例流行病学调查[J].中华医院感染学杂志,1998,8(2):95.Zhao HP, YangY. Epidemiological survey of 180 hospital infection strains[J]. Chin J Nosoloil, 1998, 8(2): 95.
[3] TzouvelekislsT, Tassios PT. CTX-M-type-beta-lactamases, an emerging group of extended-spectrum enzymes[J]. Int J Antimicrob Agents, 2000, 14: 137-42.
[4] 熊自忠.β-内酰胺酶的研究进展[J].中国抗感染化疗杂志,2001,1:61-2.Xiong ZZ. The advance in extended-spectrum β-lactamases (ESBLs)[J]. Chin J Infect Chemother, 2001, 1: 61-2.
[5] Yan JJ, Wu SN, Tsai SH, et al. Prevalence of SHV-12 among clinicai isolates of Klebsiella pneumoniae producing extended-spectrum betalactamases and identification of a novel Ampe enzyme(CMY-8)in southern[J]. TaiWan Antimicbro Agents Chemother, 2000, 44:1438-42.
[6] Gailot O, Maruejoul SC, Abachin E, et al. Nosocomial outbreak of Kebsiella pneumoniae producing SHV-5 extended-spectrum betalactamases originating from a contaminated ultrasongraphy coupling gel[J]. J Clin Microbiol, 36: 1357-60.
[7] 胡云建,杜迪君,张秀珍.产超广谱B-内酰胺酶大肠埃希菌的耐药性及脉冲电泳分型研究[J].中华医院感染学杂志,2000,10(2):154-5.Hu YJ, Du DJ, Zhang XZ, et al. Drug resistance analysis and genotype by using pulsed-field gel electrophoresis of producing extended-spectrum betaiactamases, Escherichia Coli[J]. Chin J Nosoloil, 2000, 10(2): 154-5.
[8] 苑广盈,吴耀光.产超广谱β-内酰胺酶的检测及耐药特性[J].中华医学检验杂志,1999,22(Suppl):52.Yuan GY, Wu YG. Detection and drug resistance of producing extended-spectrum betalactamases[J]. Chin J Med Clin Lab, 1999,22(Suppl): 52.
[9] 郭庆兰,宋诗铎,祁伟,等.肠杆菌科临床株产超广谱B-内酰胺酶的基因多样性研究[J].中华传染病杂志,2002,12:341-5.Guo QL, Song SD, Di W, et al. Gene diversities of ESBLs in clinical isolates of enterobacteriaceae[J]. Chin J Infect Dis, 2002, 12:341-5.